Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

posoleucel

A population of closely human leukocyte antigen (HLA)-matched, off-the-shelf (OTS), donor-derived cytotoxic T lymphocytes (CTLs) that are specifically reactive towards six viruses, Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), human herpesvirus 6 (HHV6; HHV-6), human polyomavirus type I (BKV) and human polyomavirus type II (JC virus; JCV), with potential antiviral activity. Upon infusion into allogeneic hematopoietic stem cell transplant (HSCT) recipients and immunocompromised patients, posoleucel provides virus-specific cellular immunity and causes specific anti-viral effects against active viral infections. This may prevent EBV, CMV, AdV, HHV6, BKV and JCV reactivation and infection, and inhibits viral-associated diseases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic EBV/CMV/AdV/HHV6/BKV/JCV-specific CTLs ALVR105
allogeneic multi-virus-specific CTLs ALVR105
allogeneic multi-virus-specific cytotoxic T lymphocytes ALVR105
VSTs ALVR105
US brand name:Viralym-M
Code name:ALVR 105
ALVR-105
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search